Bexarotene oral - Eisai Co Ltd
Alternative Names: BSC-1; LGD 1069; LGD 1069 oral; Targretin; Targretin capsules; Targretin oral; Targretyn oral; Targretyn™; Targrexin oralLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Ligand Pharmaceuticals
- Developer Eisai Co Ltd; Minophagen
- Class Antineoplastics; Antipsoriatics; Benzoic acids; Naphthalenes; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Protein synthesis inhibitors; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Phase II Adult T-cell leukaemia-lymphoma
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Psoriasis; Renal cell carcinoma; Thyroid cancer
Most Recent Events
- 22 Dec 2021 Minophagen Pharmaceutical completes enrollment in a phase-II trial in Adult T-cell leukaemia-lymphoma in Japan (PO) (JapicCTI-184233)
- 03 Nov 2020 Launched for Cutaneous T-cell lymphoma in Argentina (PO)
- 28 Sep 2020 Launched for Cutaneous T-cell lymphoma in Greece (PO)